)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
ABIVAX
ABIVAX (ABVX) investor relations material
ABIVAX Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary15 Dec, 2025
Executive summary
Cash and cash equivalents reached EUR 589.7M as of September 30, 2025, providing a cash runway into Q4 2027.
Key business updates included multiple late-breaking presentations of Phase 3 trial results for obefazimod in ulcerative colitis at major gastroenterology meetings.
Financial highlights
Operating loss increased by EUR 44.2M to EUR 174.4M for the nine months ending September 30, 2025, compared to the same period in 2024.
Net loss for the period was EUR 254.1M, up EUR 117.3M year-over-year.
Operating income decreased by EUR 4.0M to EUR 4.1M, mainly from lower research tax credits and subsidies.
R&D expenses rose by EUR 25.4M to EUR 133.4M, driven by increased clinical trial activity and supply chain costs.
Cash position increased by EUR 445.5M since December 31, 2024, mainly due to a large public offering in July 2025.
Outlook and guidance
Forecasted cash flow requirements are expected to be covered into Q4 2027 based on current cash reserves.
How does commercial launch prep affect cash runway?
What are next steps for Crohn's Disease program
Quantify share count increase from debt conversions
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ABIVAX
- Up to $350M in securities, including $150M ADSs via ATM, to fund R&D and growth initiatives.ABVX
Registration Filing16 Dec 2025 - 50mg oral therapy showed strong efficacy and safety in severe, refractory UC across subgroups.ABVXThe United European Gastroenterology (UEG) Congress UEG Week 202514 Dec 2025
- Obefazimod 50 mg achieved significant remission and safety in Phase 3 UC trials.ABVXStudy Result14 Oct 2025
- Positive phase 3 results and a €637.5M ($747.5M) offering extended cash runway to Q4 2027.ABVXQ2 202510 Sep 2025
- Obefazimod's Phase 3 UC trial is on track, with strong efficacy, safety, and market potential.ABVXCorporate Presentation4 Jul 2025
- Net loss widened to €81.6M as R&D spending surged, with cash runway into Q4 2025.ABVXH1 202413 Jun 2025
- Obefazimod shows promise as a differentiated oral IBD therapy with strong clinical and financial momentum.ABVXCorporate Presentation13 Jun 2025
- Net loss rose 22% in Q1 2025, with cash runway only until Q4 2025.ABVXQ1 20256 Jun 2025
- Obefazimod's Phase 3 UC trial targets a major unmet need with strong efficacy and safety data.ABVXCorporate Presentation6 Jun 2025
Next ABIVAX earnings date
Q4 202523 Mar, 2026
ABIVAX
Next ABIVAX earnings date
Q4 202523 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage